Merrimack Pharmaceuticals... (MACK)
NASDAQ: MACK
· Real-Time Price · USD
15.14
0.01 (0.07%)
At close: May 17, 2024, 9:59 PM
Merrimack Pharmaceuticals Balance Sheet Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Cash & Equivalents | 234.16M | 5.99M | 6.08M | 10.13M | 19.4M | 19.44M | 13.09M | 13.36M | 14.29M | 14.2M | 14.56M | 14.91M | 13.89M |
Short-Term Investments | 9.95M | 12.89M | 12.82M | 8.84M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Long-Term Investments | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Assets | 3K | 4K | 5K | 6K | 7K | 8K | 9K | 10K | 25K | 66K | 108K | 149K | 191K |
Receivables | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Inventory | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Current Assets | 209K | 309K | 390K | 474K | 227K | 389K | 537K | 690K | 320K | 480K | 636K | 805K | 2.36M |
Total Current Assets | 244.32M | 19.18M | 19.29M | 19.44M | 19.63M | 19.83M | 13.63M | 14.04M | 14.61M | 14.68M | 15.19M | 15.71M | 16.25M |
Property-Plant & Equipment | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Goodwill & Intangibles | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Assets | 3K | 4K | 5K | 6K | 7K | 8K | 9K | 10K | 25K | 66K | 108K | 149K | 191K |
Total Assets | 244.32M | 19.19M | 19.3M | 19.45M | 19.64M | 19.84M | 13.64M | 14.05M | 14.64M | 14.75M | 15.3M | 15.86M | 16.44M |
Account Payables | 168K | 74K | 111K | 80K | 89K | 188K | 67K | 84K | 177K | 120K | 104K | 173K | 108K |
Deferred Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Short-Term Debt | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Current Liabilities | 22.5M | 367K | 382K | 331K | 374K | 401K | 381K | 357K | 387K | 442K | 579K | 599K | 576K |
Total Current Liabilities | 22.67M | 441K | 493K | 411K | 463K | 589K | 448K | 441K | 564K | 562K | 683K | 772K | 684K |
Long-Term Debt | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Long-Term Liabilities | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Total Long-Term Liabilities | n/a | n/a | n/a | n/a | 89K | 589K | 67K | 84K | 177K | 120K | n/a | n/a | n/a |
Total Liabilities | 22.67M | 441K | 493K | 411K | 463K | 589K | 448K | 441K | 564K | 562K | 683K | 772K | 684K |
Total Debt | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Common Stock | 1.34M | 1.34M | 1.34M | 1.34M | 1.34M | 1.34M | 1.33M | 1.33M | 1.33M | 1.33M | 1.33M | 1.33M | 1.33M |
Retained Earnings | -347.45M | -548.82M | -548.58M | -548.3M | -547.91M | -547.64M | -547.14M | -546.7M | -546.22M | -546.09M | -545.62M | -545.09M | -544.33M |
Comprehensive Income | n/a | n/a | n/a | n/a | n/a | -0.00 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shareholders Equity | 221.65M | 18.75M | 18.81M | 19.04M | 19.17M | 19.25M | 13.19M | 13.61M | 14.07M | 14.19M | 14.62M | 15.09M | 15.76M |
Total Investments | 9.95M | 12.89M | 12.82M | 8.84M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |